Prime Medicine, Inc. (PRME) Announces NEJM Release of PM359 Data
Prime Medicine, Inc. (NASDAQ:PRME) is among the The 12 best genomics stocks to invest in. Prime Medicine Announces NEJM Release of PM359 Data Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025 that the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic stem cell therapy for…